Germany · Delayed Price · Currency is EUR Recce Pharmaceuticals Statistics
Total Valuation
FRA:R9Q has a market cap or net worth of EUR 88.00 million. The enterprise value is 88.05 million.
| Market Cap | 88.00M |
| Enterprise Value | 88.05M |
Important Dates
The last earnings date was Wednesday, November 26, 2025.
| Earnings Date | Nov 26, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 289.18M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +33.81% |
| Shares Change (QoQ) | +6.97% |
| Owned by Insiders (%) | 38.94% |
| Owned by Institutions (%) | 14.84% |
| Float | 160.67M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 20.99 |
| PB Ratio | -51.65 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -7.36 |
| EV / Sales | 20.81 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -7.71 |
Financial Position
The company has a current ratio of 1.86
| Current Ratio | 1.86 |
| Quick Ratio | 1.78 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.53 |
| Interest Coverage | -16.87 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -135.80% |
| Return on Invested Capital (ROIC) | -293.44% |
| Return on Capital Employed (ROCE) | -324.67% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.80 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -3.13% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -3.13% |
| 50-Day Moving Average | 0.21 |
| 200-Day Moving Average | 0.19 |
| Relative Strength Index (RSI) | 67.23 |
| Average Volume (20 Days) | n/a |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, FRA:R9Q had revenue of EUR 4.19 million and -11.96 million in losses. Loss per share was -0.05.
| Revenue | 4.19M |
| Gross Profit | -1.64M |
| Operating Income | -11.39M |
| Pretax Income | -11.96M |
| Net Income | -11.96M |
| EBITDA | -11.35M |
| EBIT | -11.39M |
| Loss Per Share | -0.05 |
Balance Sheet
The company has 5.97 million in cash and 6.01 million in debt, giving a net cash position of -46,227.
| Cash & Cash Equivalents | 5.97M |
| Total Debt | 6.01M |
| Net Cash | -46,227 |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -1.70M |
| Book Value Per Share | -0.01 |
| Working Capital | 2.93M |
Cash Flow
In the last 12 months, operating cash flow was -11.41 million and capital expenditures -14,708, giving a free cash flow of -11.43 million.
| Operating Cash Flow | -11.41M |
| Capital Expenditures | -14,708 |
| Free Cash Flow | -11.43M |
| FCF Per Share | n/a |
Margins
Gross margin is -39.12%, with operating and profit margins of -271.76% and -285.37%.
| Gross Margin | -39.12% |
| Operating Margin | -271.76% |
| Pretax Margin | -285.37% |
| Profit Margin | -285.37% |
| EBITDA Margin | -270.81% |
| EBIT Margin | -271.76% |
| FCF Margin | n/a |
Dividends & Yields
FRA:R9Q does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -33.81% |
| Shareholder Yield | -33.81% |
| Earnings Yield | -13.59% |
| FCF Yield | -12.98% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
FRA:R9Q has an Altman Z-Score of -10.7 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -10.7 |
| Piotroski F-Score | 2 |